X4 Pharmaceuticals, Inc
XFOR evidence brief
What we can confirm
- BioSniper Score:
- 5.3 / 10
- Market Cap:
- $344.5M
- Lead Asset:
- xolremdi (Approved)
What it means
What to watch
Prepared research question
What matters most for XFOR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XFOR
X4 Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapeutics for rare hematology diseases, with a focus on its lead drug candidate mavorixafor for chronic neutropenia and WHIM syndrome.
Key risk: Operating losses and capital needs
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 catalyst for X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapeutics for rare hematology diseases, with a focus on its lead drug candidate mavorixafor for chronic neutropenia and WHIM syndrome.
- X4 Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases [sec_mda · as of 2026-08-06].
- The company is progressing its global, pivotal Phase 3 clinical trial (the '4WARD' trial) evaluating oral, once-daily mavorixafor for chronic neutropenic disorders [sec_mda · as of 2026-08-06].
- As of 2026-06-30, X4 reported cash & equivalents of $195.1M, net income of -$16.2M, and shareholders' equity of $155.5M [sec].
- In October 2026, X4 secured a senior secured term loan facility of up to $150 million with K2 HealthVentures to strengthen financial flexibility [news · published 2026-10-08].
- The FDA agreed to a reduced sample size for the 4WARD trial, with enrollment expected to complete by year-end 2026 and topline data expected in H1 2028 [news · published 2026-09-08].
What works
- X4 has a clear focus on rare hematology diseases with a lead candidate, mavorixafor, that has advanced to a pivotal Phase 3 trial (4WARD) [sec_mda · as of 2026-08-06].
- The company secured a $150 million senior debt facility with K2 HealthVentures, enhancing its financial flexibility for corporate and commercial activities [news · published 2026-10-08].
- FDA agreement to a reduced sample size for the 4WARD trial may streamline the path to topline data, expected in H1 2028 [news · published 2026-09-08].
What to weigh
- X4 continues to incur operating losses, with a net income of -$16.2M as of 2026-06-30, and expects to require additional capital to fund operations until profitability [sec] [sec_mda · as of 2026-08-06].
- The company faces numerous risks and uncertainties in funding requirements, including the scope, timing, and costs of clinical trials, particularly the Phase 3 mavorixafor trial [sec_mda · as of 2026-08-06].
- If additional funding cannot be obtained, X4 may be forced to delay, reduce, or eliminate R&D programs or commercialization efforts, potentially affecting business prospects [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
X4 is a biopharmaceutical company developing and commercializing novel therapeutics for rare hematology diseases.
“We are a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases.”
SEC MD&A · August 6, 2026
The company is progressing its pivotal Phase 3 4WARD trial for mavorixafor.
“We continue to progress our global, pivotal Phase 3 clinical trial, (the "4WARD" trial) to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor”
SEC MD&A · August 6, 2026
X4 secured a $150 million senior debt facility with K2 HealthVentures.
“X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures”
News · October 8, 2026
FDA agreed to a reduced sample size for the 4WARD trial.
“FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial”
News · September 8, 2026
Catalyst timeline
- 2038-12-11 · Patent_Expiry · MAVORIXAFOR — Patent_Expiry: NDA218709 — Patent expiry for mavorixafor, which may affect future market exclusivity.
Risks & what to watch (3)›
Key risks
- Operating losses and capital needs — X4 reported net income of -$16.2M as of 2026-06-30 and expects to need additional capital to fund operations until profitability [sec] [sec_mda · as of 2026-08-06].
- Clinical trial uncertainties — Funding requirements depend on scope, timing, costs, and results of the Phase 3 mavorixafor trial, which could increase significantly [sec_mda · as of 2026-08-06].
- Funding dependency risk — If unable to obtain funding, X4 may delay or eliminate R&D programs or commercialization, adversely affecting business prospects [sec_mda · as of 2026-08-06].
What to watch
- Completion of enrollment in the Phase 3 4WARD trial by year-end 2026 [news · published 2026-10-08].
- Topline data from the 4WARD trial expected in H1 2028 [news · published 2026-09-08].
- X4's ability to manage cash runway and secure additional funding given operating losses [sec] [sec_mda · as of 2026-08-06].
- Regulatory developments and potential commercialization of mavorixafor for chronic neutropenia [sec_mda · as of 2026-08-06].
Sources: Catalysts · News · SEC MD&A · Generated October 9, 2026 · How we verify sources →
Run X4 Pharmaceuticals, Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available X4 Pharmaceuticals, Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.63 · 0% dilution
Lead: Approved
1 candidate
1 upcoming, next in ~4440d
0 buys · 4 sells (180d)
Catalysts
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
82
Total value held
$392.6M
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 9,466,992 | $39.1M |
| empery asset management, lp | 8,944,118 | $36.9M |
| fmr llc | 8,103,400 | $33.5M |
| bain capital life sciences investors, llc | 7,967,454 | $32.9M |
| kalehua capital management llc | 7,445,680 | $30.8M |
| perceptive advisors llc | 6,737,648 | $27.8M |
| saturn v capital management lp | 6,456,646 | $26.7M |
| deep track capital, lp | 6,339,535 | $26.2M |
| vanguard capital management llc | 3,497,612 | $14.4M |
| braidwell lp | 3,272,954 | $13.5M |
Showing top 10 of 82 institutional holders of X4 Pharmaceuticals, Inc. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 3.3%
- Days to cover
- 7.9
- Shares short
- 3,117,372
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XFOR short interestGovernance
Frequently asked questions
What is the AI investment thesis for X4 Pharmaceuticals, Inc?
X4 Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapeutics for rare hematology diseases, with a focus on its lead drug candidate mavorixafor for chronic neutropenia and WHIM syndrome.
What is X4 Pharmaceuticals, Inc's lead drug candidate?
X4 Pharmaceuticals, Inc's most advanced tracked candidate is xolremdi (Approved) for WHIM syndrome.
What is X4 Pharmaceuticals, Inc's next catalyst?
X4 Pharmaceuticals, Inc's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA218709" — expected December 11, 2038.
Who is the CEO of X4 Pharmaceuticals, Inc?
Radius Health is the chief executive officer of X4 Pharmaceuticals, Inc (XFOR).
Where is X4 Pharmaceuticals, Inc headquartered?
X4 Pharmaceuticals, Inc (XFOR) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.